Future directions in the treatment of Parkinson's disease
Identifieur interne : 000E65 ( Istex/Corpus ); précédent : 000E64; suivant : 000E66Future directions in the treatment of Parkinson's disease
Auteurs : Anthony H. V. SchapiraSource :
- Movement Disorders [ 0885-3185 ] ; 2007.
English descriptors
- KwdEn :
Abstract
The development of treatment for the symptoms of Parkinson's disease (PD) has been one of the most notable successes of neurology. Dopaminergic therapies in the form of levodopa, dopamine agonists, or monoamine oxidase B inhibitors significantly improve the characteristic motor symptoms of bradykinesia and rigidity, with a beneficial effect upon tremor in a proportion of patients. Novel delivery of dopaminergic drugs whether in the form of once a day sustained release preparations or transdermal applications ensures that they remain at the forefront of PD treatment. The development of drugs to slow the progression of PD has attracted considerable attention and there appears to be some measure of success although additional studies need to be performed. A range of nondopaminergic drugs including alpha 2‐adrenergic antagonists, serotoninergics, and adenosine A2a antagonists are in late‐stage development for PD and offer benefit for motor symptoms and motor complications. © 2007 Movement Disorder Society
Url:
DOI: 10.1002/mds.21679
Links to Exploration step
ISTEX:17DC5AE4B28D6BD4538FACE203DB294ECCA42140Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Future directions in the treatment of Parkinson's disease</title><author><name sortKey="Schapira, Anthony H V" sort="Schapira, Anthony H V" uniqKey="Schapira A" first="Anthony H. V." last="Schapira">Anthony H. V. Schapira</name><affiliation><mods:affiliation>University Department of Clinical Neurosciences, Royal Free and University College Medical School, University College London, London, United Kingdom</mods:affiliation></affiliation><affiliation><mods:affiliation>Institute of Neurology, University College London, London, United Kingdom</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:17DC5AE4B28D6BD4538FACE203DB294ECCA42140</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1002/mds.21679</idno><idno type="url">https://api.istex.fr/document/17DC5AE4B28D6BD4538FACE203DB294ECCA42140/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000E65</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Future directions in the treatment of Parkinson's disease</title><author><name sortKey="Schapira, Anthony H V" sort="Schapira, Anthony H V" uniqKey="Schapira A" first="Anthony H. V." last="Schapira">Anthony H. V. Schapira</name><affiliation><mods:affiliation>University Department of Clinical Neurosciences, Royal Free and University College Medical School, University College London, London, United Kingdom</mods:affiliation></affiliation><affiliation><mods:affiliation>Institute of Neurology, University College London, London, United Kingdom</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2007">2007</date><biblScope unit="vol">22</biblScope><biblScope unit="issue">S17</biblScope><biblScope unit="supplement">S17</biblScope><biblScope unit="page" from="S385">S385</biblScope><biblScope unit="page" to="S391">S391</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">17DC5AE4B28D6BD4538FACE203DB294ECCA42140</idno><idno type="DOI">10.1002/mds.21679</idno><idno type="ArticleID">MDS21679</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>MAOB inhibitors</term><term>Parkinson's disease</term><term>adenosine A2a antagonists.</term><term>dopamine agonists</term><term>neuroprotection</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The development of treatment for the symptoms of Parkinson's disease (PD) has been one of the most notable successes of neurology. Dopaminergic therapies in the form of levodopa, dopamine agonists, or monoamine oxidase B inhibitors significantly improve the characteristic motor symptoms of bradykinesia and rigidity, with a beneficial effect upon tremor in a proportion of patients. Novel delivery of dopaminergic drugs whether in the form of once a day sustained release preparations or transdermal applications ensures that they remain at the forefront of PD treatment. The development of drugs to slow the progression of PD has attracted considerable attention and there appears to be some measure of success although additional studies need to be performed. A range of nondopaminergic drugs including alpha 2‐adrenergic antagonists, serotoninergics, and adenosine A2a antagonists are in late‐stage development for PD and offer benefit for motor symptoms and motor complications. © 2007 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Anthony H.V. Schapira MD, DSc, FRCP, FMedSci</name><affiliations><json:string>University Department of Clinical Neurosciences, Royal Free and University College Medical School, University College London, London, United Kingdom</json:string><json:string>Institute of Neurology, University College London, London, United Kingdom</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>neuroprotection</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>MAOB inhibitors</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>dopamine agonists</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>adenosine A2a antagonists.</value></json:item></subject><language><json:string>eng</json:string></language><abstract>The development of treatment for the symptoms of Parkinson's disease (PD) has been one of the most notable successes of neurology. Dopaminergic therapies in the form of levodopa, dopamine agonists, or monoamine oxidase B inhibitors significantly improve the characteristic motor symptoms of bradykinesia and rigidity, with a beneficial effect upon tremor in a proportion of patients. Novel delivery of dopaminergic drugs whether in the form of once a day sustained release preparations or transdermal applications ensures that they remain at the forefront of PD treatment. The development of drugs to slow the progression of PD has attracted considerable attention and there appears to be some measure of success although additional studies need to be performed. A range of nondopaminergic drugs including alpha 2‐adrenergic antagonists, serotoninergics, and adenosine A2a antagonists are in late‐stage development for PD and offer benefit for motor symptoms and motor complications. © 2007 Movement Disorder Society</abstract><qualityIndicators><score>6.788</score><pdfVersion>1.3</pdfVersion><pdfPageSize>594 x 792 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>1016</abstractCharCount><pdfWordCount>5096</pdfWordCount><pdfCharCount>33203</pdfCharCount><pdfPageCount>7</pdfPageCount><abstractWordCount>149</abstractWordCount></qualityIndicators><title>Future directions in the treatment of Parkinson's disease</title><genre><json:string>Serial article</json:string></genre><host><volume>22</volume><pages><total>7</total><last>S391</last><first>S385</first></pages><issn><json:string>0885-3185</json:string></issn><issue>S17</issue><subject><json:item><value>Research Article</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2007</publicationDate><copyrightDate>2007</copyrightDate><doi><json:string>10.1002/mds.21679</json:string></doi><id>17DC5AE4B28D6BD4538FACE203DB294ECCA42140</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/17DC5AE4B28D6BD4538FACE203DB294ECCA42140/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/17DC5AE4B28D6BD4538FACE203DB294ECCA42140/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/17DC5AE4B28D6BD4538FACE203DB294ECCA42140/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Future directions in the treatment of Parkinson's disease</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Wiley Subscription Services, Inc., A Wiley Company</p></availability><date>2007</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Future directions in the treatment of Parkinson's disease</title><author><persName><forename type="first">Anthony H.V.</forename><surname>Schapira</surname><roleName type="degree">MD, DSc, FRCP, FMedSci</roleName></persName><note type="correspondence"><p>Correspondence: University Department of Clinical Neurosciences, Royal Free and University College Medical School, Rowland Hill Street, London NW3 2PF, United Kingdom</p></note><affiliation>University Department of Clinical Neurosciences, Royal Free and University College Medical School, University College London, London, United Kingdom</affiliation><affiliation>Institute of Neurology, University College London, London, United Kingdom</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2007"></date><biblScope unit="vol">22</biblScope><biblScope unit="issue">S17</biblScope><biblScope unit="supplement">S17</biblScope><biblScope unit="page" from="S385">S385</biblScope><biblScope unit="page" to="S391">S391</biblScope></imprint></monogr><idno type="istex">17DC5AE4B28D6BD4538FACE203DB294ECCA42140</idno><idno type="DOI">10.1002/mds.21679</idno><idno type="ArticleID">MDS21679</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2007</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>The development of treatment for the symptoms of Parkinson's disease (PD) has been one of the most notable successes of neurology. Dopaminergic therapies in the form of levodopa, dopamine agonists, or monoamine oxidase B inhibitors significantly improve the characteristic motor symptoms of bradykinesia and rigidity, with a beneficial effect upon tremor in a proportion of patients. Novel delivery of dopaminergic drugs whether in the form of once a day sustained release preparations or transdermal applications ensures that they remain at the forefront of PD treatment. The development of drugs to slow the progression of PD has attracted considerable attention and there appears to be some measure of success although additional studies need to be performed. A range of nondopaminergic drugs including alpha 2‐adrenergic antagonists, serotoninergics, and adenosine A2a antagonists are in late‐stage development for PD and offer benefit for motor symptoms and motor complications. © 2007 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Parkinson's disease</term></item><item><term>neuroprotection</term></item><item><term>MAOB inhibitors</term></item><item><term>dopamine agonists</term></item><item><term>adenosine A2a antagonists.</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Research Article</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2007-04-20">Received</change><change when="2007-07-02">Registration</change><change when="2007">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/17DC5AE4B28D6BD4538FACE203DB294ECCA42140/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="subtitle">Official Journal of the Movement Disorder Society</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="75"><doi origin="wiley" registered="yes">10.1002/mds.v22:17+</doi><titleGroup><title type="supplementTitle">10th International Symposium on the Treatment of Parkinson's Disease</title></titleGroup><numberingGroup><numbering type="journalVolume" number="22">22</numbering><numbering type="journalIssue">S17</numbering><numbering type="supplement" number="S17">S17</numbering></numberingGroup><coverDate startDate="2007">2007</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="100" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.21679</doi><idGroup><id type="unit" value="MDS21679"></id></idGroup><countGroup><count type="pageTotal" number="7"></count></countGroup><titleGroup><title type="articleCategory">Research Article</title><title type="tocHeading1">Research Articles</title></titleGroup><copyright ownership="thirdParty">Copyright © 2007 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2007-04-20"></event><event type="manuscriptAccepted" date="2007-07-02"></event><event type="firstOnline" date="2007-12-14"></event><event type="publishedOnlineFinalForm" date="2007-12-14"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.3.2 mode:FullText source:FullText result:FullText" date="2010-03-09"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">S385</numbering><numbering type="pageLast">S391</numbering></numberingGroup><correspondenceTo>University Department of Clinical Neurosciences, Royal Free and University College Medical School, Rowland Hill Street, London NW3 2PF, United Kingdom</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS21679.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="0"></count><count type="referenceTotal" number="85"></count><count type="wordTotal" number="5624"></count></countGroup><titleGroup><title type="main" xml:lang="en">Future directions in the treatment of Parkinson's disease</title><title type="short" xml:lang="en">Future Treatment in Parkinson's Disease</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1 #af2" corresponding="yes"><personName><givenNames>Anthony H.V.</givenNames><familyName>Schapira</familyName><degrees>MD, DSc, FRCP, FMedSci</degrees></personName><contactDetails><email>a.schapira@medsch.ucl.ac.uk</email></contactDetails></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="GB" type="organization"><unparsedAffiliation>University Department of Clinical Neurosciences, Royal Free and University College Medical School, University College London, London, United Kingdom</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="GB" type="organization"><unparsedAffiliation>Institute of Neurology, University College London, London, United Kingdom</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Parkinson's disease</keyword><keyword xml:id="kwd2">neuroprotection</keyword><keyword xml:id="kwd3">MAOB inhibitors</keyword><keyword xml:id="kwd4">dopamine agonists</keyword><keyword xml:id="kwd5">adenosine A2a antagonists.</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>The development of treatment for the symptoms of Parkinson's disease (PD) has been one of the most notable successes of neurology. Dopaminergic therapies in the form of levodopa, dopamine agonists, or monoamine oxidase B inhibitors significantly improve the characteristic motor symptoms of bradykinesia and rigidity, with a beneficial effect upon tremor in a proportion of patients. Novel delivery of dopaminergic drugs whether in the form of once a day sustained release preparations or transdermal applications ensures that they remain at the forefront of PD treatment. The development of drugs to slow the progression of PD has attracted considerable attention and there appears to be some measure of success although additional studies need to be performed. A range of nondopaminergic drugs including alpha 2‐adrenergic antagonists, serotoninergics, and adenosine A2a antagonists are in late‐stage development for PD and offer benefit for motor symptoms and motor complications. © 2007 Movement Disorder Society</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 3-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Future directions in the treatment of Parkinson's disease</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Future Treatment in Parkinson's Disease</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Future directions in the treatment of Parkinson's disease</title></titleInfo><name type="personal"><namePart type="given">Anthony H.V.</namePart><namePart type="family">Schapira</namePart><namePart type="termsOfAddress">MD, DSc, FRCP, FMedSci</namePart><affiliation>University Department of Clinical Neurosciences, Royal Free and University College Medical School, University College London, London, United Kingdom</affiliation><affiliation>Institute of Neurology, University College London, London, United Kingdom</affiliation><description>Correspondence: University Department of Clinical Neurosciences, Royal Free and University College Medical School, Rowland Hill Street, London NW3 2PF, United Kingdom</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">article</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2007</dateIssued><dateCaptured encoding="w3cdtf">2007-04-20</dateCaptured><dateValid encoding="w3cdtf">2007-07-02</dateValid><copyrightDate encoding="w3cdtf">2007</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="references">85</extent><extent unit="words">5624</extent></physicalDescription><abstract lang="en">The development of treatment for the symptoms of Parkinson's disease (PD) has been one of the most notable successes of neurology. Dopaminergic therapies in the form of levodopa, dopamine agonists, or monoamine oxidase B inhibitors significantly improve the characteristic motor symptoms of bradykinesia and rigidity, with a beneficial effect upon tremor in a proportion of patients. Novel delivery of dopaminergic drugs whether in the form of once a day sustained release preparations or transdermal applications ensures that they remain at the forefront of PD treatment. The development of drugs to slow the progression of PD has attracted considerable attention and there appears to be some measure of success although additional studies need to be performed. A range of nondopaminergic drugs including alpha 2‐adrenergic antagonists, serotoninergics, and adenosine A2a antagonists are in late‐stage development for PD and offer benefit for motor symptoms and motor complications. © 2007 Movement Disorder Society</abstract><subject lang="en"><genre>Keywords</genre><topic>Parkinson's disease</topic><topic>neuroprotection</topic><topic>MAOB inhibitors</topic><topic>dopamine agonists</topic><topic>adenosine A2a antagonists.</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title><subTitle>Official Journal of the Movement Disorder Society</subTitle></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><subject><genre>article category</genre><topic>Research Article</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><detail type="issue"><caption>no.</caption><number>S17</number></detail><detail type="supplement"><caption>Suppl. no.</caption><number>S17</number></detail><extent unit="pages"><start>S385</start><end>S391</end><total>7</total></extent></part></relatedItem><identifier type="istex">17DC5AE4B28D6BD4538FACE203DB294ECCA42140</identifier><identifier type="DOI">10.1002/mds.21679</identifier><identifier type="ArticleID">MDS21679</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2007 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E65 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000E65 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:17DC5AE4B28D6BD4538FACE203DB294ECCA42140
|texte= Future directions in the treatment of Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |